Hematological Oncology

Papers
(The H4-Index of Hematological Oncology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP63
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)52
THE POTENTIAL EFFICACY AND MECHANISM OF BENDAMUSTINE IN ENTRA‐NODAL NK/T CELL LYMPHOMA35
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S001633
PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐528
28
CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSICAL HODGKIN LYMPHOMA27
Regulatory approvals and survival benefit for novel lymphoma drugs from 2013–202226
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis26
A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS25
REAL‐WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA24
CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORK23
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived Models22
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)22
PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (LOTIS‐7)22
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma21
QUALITY OF LIFE IN PEDIATRIC HIGH‐RISK HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐BASED INTENSIVE CHEMOTHERAPY—COMPARISON TO HISTORICAL TREATMENT COHORT AND HEALTHY PEERS21
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY21
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphoma21
ENHANCER RNAS (ERNAS) PLAY A ROLE IN THE RESPONSE TO SMALL MOLECULES AND IN THE DEVELOPMENT OF ACQUIRED RESISTANCE IN MARGINAL ZONE LYMPHOMA (MZL)20
PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS20
EFFICACY OF FRONT‐LINE IMMUNOCHEMOTHERAPY FOR TRANSPLANT‐INELIGIBLE MANTLE CELL LYMPHOMA: A NETWORK META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS20
0.34533882141113